SpaceX Enters $40 Billion Finance Lease with Apollo Management
SpaceX has entered a master finance lease with Apollo Global Management for $40 billion, aimed at enhancing its data center capabilities.
Oruka Therapeutics reports positive Phase 2b trial results
Oruka Therapeutics announces encouraging results from its Phase 2b trial of ORKA-001 for psoriasis, paving the way for Phase 3 trials in 2027.
Zeo ScientifiX Partners with Pluri to Expand Manufacturing
Zeo ScientifiX announces a strategic partnership with Pluri Inc. to enhance U.S. manufacturing and commercialization in regenerative medicine and aesthetics.
Getty Images Files for Chapter 11 Bankruptcy Protection
Getty Images Holdings, Inc. has filed for Chapter 11 bankruptcy, seeking to restructure its debts with up to $143 million in financing.
Braemar Hotels & Resorts nominates eight for board election
Braemar Hotels & Resorts Inc. announces nomination of eight new directors to strengthen leadership amid competitive real estate investment trust sector.
Cyber Enviro-Tech Amends Equity Purchase Agreement with Investor
Cyber Enviro-Tech, Inc. modifies its equity purchase agreement, allowing for a more flexible pricing structure to enhance capital-raising capabilities.
Oaktree Acquisition Corp. III Life Sciences extends business deadline
Oaktree Acquisition Corp. III Life Sciences extends its deadline to complete a business combination to November 25, 2026, impacting its strategic direction.
Phathom Pharmaceuticals Responds to FDA Docket on VOQUEZNA
Phathom Pharmaceuticals reacts to FDA's public docket on VOQUEZNA's exclusivity, amid ongoing litigation with BDR Pharmaceuticals.
Elme Communities to Delist from NYSE Amid Liquidation Plans
Elme Communities is set to delist from the NYSE due to low stock prices and will begin trading OTC as it moves forward with liquidation plans.
Bio Essence Corp adds new directors, amends bylaws
Bio Essence Corp appoints Thea Zhang and Geoff Fellows to its board, expanding governance and operational capabilities while amending bylaws for a larger board.
Eikon Therapeutics presents clinical data at oncology congress
Eikon Therapeutics shares promising clinical data from its PARP1 and WRN helicase programs at the European Society for Medical Oncology Congress.
ENB Financial Corp Reports Strong Q3 2026 Earnings Growth
ENB Financial Corp announces a 16.8% rise in Q3 net income, reflecting successful integration of Cecil Bancorp and robust loan growth.
Stewart Information Services reports Q3 2026 financial results
Stewart Information Services Corp reports Q3 2026 results, showing revenue growth but a decline in net income amid industry challenges.
Consumer Portfolio Services Reports Strong Q3 2026 Results
Consumer Portfolio Services, Inc. announces impressive Q3 results with significant growth in net income and loan origination, impacting the finance services sector.
Oak Valley Bancorp reports strong Q3 results with higher income
Oak Valley Bancorp announces increased net income and improved margins for Q3 2026, reflecting strong operational performance in the state commercial banking sector.
Eagle Bancorp Reports Q3 2026 Results, Declares Dividend
Eagle Bancorp, Inc. announces significant Q3 2026 results with increased net income and a cash dividend, reflecting strategic growth in the commercial banking sector.
Ionis Pharmaceuticals Reports Positive Phase 3 Results for Sefaxersen
Ionis Pharmaceuticals announces a 43.1% reduction in proteinuria with sefaxersen, a potential treatment for IgA nephropathy, based on Phase 3 study results.
Federal Home Loan Bank of Boston Elects Four New Directors
Federal Home Loan Bank of Boston announces election of four new directors effective January 1, 2027, alongside updated compensation policies.
Procaccianti Hotel REIT modifies loan, extends maturity date
Procaccianti Hotel REIT, Inc. modifies loan terms to increase borrowing capacity and extends maturity date, supporting renovations at Hotel Indigo.
Zymeworks Enters Major Collaboration with Roche for ZW209
Zymeworks has signed a collaboration agreement with Roche, granting exclusive rights to develop ZW209, a promising cancer treatment, with significant financial incentives.